About Ocular Therapeutix
Ocular Therapeutix is a company based in Bedford (United States) founded in 2006.. Ocular Therapeutix has raised $89.45 million across 8 funding rounds from investors including Baxter, Ascension Ventures and Polaris Partners. The company has 274 employees as of December 31, 2024. Ocular Therapeutix offers products and services including DEXTENZA, AXPAXLI, PAXTRAVA, and ReSure Sealant. Ocular Therapeutix operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
- Headquarter Bedford, United States
- Employees 274 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ocular Therapeutix, Inc.
-
Annual Revenue
$63.72 M9.03as on Dec 31, 2024
-
Net Profit
$-193.51 M-139.68as on Dec 31, 2024
-
EBITDA
$-168 M-111.58as on Dec 31, 2024
-
Total Equity Funding
$89.45 M (USD)
in 8 rounds
-
Latest Funding Round
$8.5 M (USD), Series D
Jun 07, 2013
-
Investors
Baxter
& 6 more
-
Employee Count
274
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ocular Therapeutix
Ocular Therapeutix is a publicly listed company on the NASDAQ with ticker symbol OCUL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ocular Therapeutix
Ocular Therapeutix offers a comprehensive portfolio of products and services, including DEXTENZA, AXPAXLI, PAXTRAVA, and ReSure Sealant. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Sustained-release insert for treating eye inflammation and pain.
Delivers axitinib to manage retinal diseases effectively.
Provides travoprost for glaucoma treatment over time.
Used to seal wounds in ocular surgeries securely.
Unlock access to complete
Unlock access to complete
Funding Insights of Ocular Therapeutix
Ocular Therapeutix has successfully raised a total of $89.45M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $8.5 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series D — $8.5M
- First Round First Round
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2013 | Amount | Series D - Ocular Therapeutix | Valuation |
investors |
|
| Jan, 2013 | Amount | Series D - Ocular Therapeutix | Valuation |
investors |
|
| Feb, 2011 | Amount | Series D - Ocular Therapeutix | Valuation | Ascension Ventures , SV Health Investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ocular Therapeutix
Ocular Therapeutix has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Baxter, Ascension Ventures and Polaris Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Strategic investments in healthcare technologies and data innovations.
|
Founded Year | Domain | Location | |
|
US focused venture capital firm
|
Founded Year | Domain | Location | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ocular Therapeutix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ocular Therapeutix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ocular Therapeutix Comparisons
Competitors of Ocular Therapeutix
Ocular Therapeutix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| domain | founded_year | HQ Location |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| domain | founded_year | HQ Location |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| domain | founded_year | HQ Location |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ocular Therapeutix
Frequently Asked Questions about Ocular Therapeutix
When was Ocular Therapeutix founded?
Ocular Therapeutix was founded in 2006.
Where is Ocular Therapeutix located?
Ocular Therapeutix is headquartered in Bedford, United States.
Is Ocular Therapeutix a funded company?
Ocular Therapeutix is a funded company, having raised a total of $89.45M across 8 funding rounds to date. The company's 1st funding round was a Series D of $14M, raised on Jun 01, 2006.
How many employees does Ocular Therapeutix have?
As of Dec 31, 2024, the latest employee count at Ocular Therapeutix is 274.
What is the annual revenue of Ocular Therapeutix?
Annual revenue of Ocular Therapeutix is $63.72M as on Dec 31, 2024.
What does Ocular Therapeutix do?
Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, United States. Operations center on the development and commercialization of therapies for ocular conditions through a proprietary hydrogel platform. Products include ReSure Sealant for sealing corneal incisions post-cataract surgery, along with treatments for post-surgical inflammation, pain, allergic conjunctivitis, glaucoma, and dry eye disease. An injectable anti-VEGF therapy for eye diseases is also under development.
Who are the top competitors of Ocular Therapeutix?
Ocular Therapeutix's top competitors include Annexon, Alimera Sciences and MeiraGTx.
What products or services does Ocular Therapeutix offer?
Ocular Therapeutix offers DEXTENZA, AXPAXLI, PAXTRAVA, and ReSure Sealant.
Is Ocular Therapeutix publicly traded?
Yes, Ocular Therapeutix is publicly traded on NASDAQ under the ticker symbol OCUL.
Who are Ocular Therapeutix's investors?
Ocular Therapeutix has 7 investors. Key investors include Baxter, Ascension Ventures, Polaris Partners, Versant Ventures, and SV Health Investors.
What is Ocular Therapeutix's ticker symbol?
The ticker symbol of Ocular Therapeutix is OCUL on NASDAQ.